ArticleFrontiers in bioengineering and biotechnology2023
Interpretatively automated identification of circulating tumor cells from human peripheral blood with high performance.
Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection and analysis of circulating tumor cells (CTCs) would be of aid in a precise cancer diagnosis and an efficient prognosis assessment. However, traditional methods that rely heavily on the isolation of CTCs based on their physical or biological features suffer from intensive labor, thus being unsuitable for rapid detection. Furthermore, currently available intelligent methods are short of interpretability, which creates a lot of uncertainty during diagnosis. Therefore, we propose here an automated method that takes advantage of bright-field microscopic images with high resolution, so as to take an insight into cell patterns. Specifically, the precise identification of CTCs was achieved by using an optimized single-shot multi-box detector (SSD)-based neural network with integrated attention mechanism and feature fusion modules. Compared to the conventional SSD system, our method exhibited a superior detection performance with the recall rate of 92.2%, and the maximum average precision (AP) value of 97.9%. To note, the optimal SSD-based neural network was combined with advanced visualization technology, i.e., the gradient-weighted class activation mapping (Grad-CAM) for model interpretation, and the t-distributed stochastic neighbor embedding (T-SNE) for data visualization. Our work demonstrates for the first time the outstanding performance of SSD-based neural network for CTCs identification in human peripheral blood environment, showing great potential for the early detection and continuous monitoring of cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.